Manuscripts

Year JournalTITLEAuthorsDOI
2017GUTSofosbuvir plus Ribavirin for the Treatment of HCV Genotype 2 Infection: Results of the Real-World, Clinical Practice HCV-TARGET Study (G2)Tania M. Welzel1, David R. Nelson2, Giuseppe Morelli; Adrian Di Bisceglie; Raj Reddy; Alexander Kuo; Joseph K. Lim; Jama Darling; Paul Pockros; Joseph Galati; Lynn M. Frazier; Saleh Alqahtani; Mark S. Sulkowski; Monika Vainorius, Lucy Akushevich, Michael W. Fried; Stefan Zeuzem1 PMID: 27418632
DOI: 10.1136/gutjnl-2016-311609
2016Gastro-enterologyEffectiveness of Ledipasvir-sofosbuvir Combination in Patients with Hepatitis C Virus Infection and Factors Associated of Sustained Virologic ResponseNorah Terrault, Stefan Zeuzem, Adrian M Di Bisceglie, Joseph K Lim, Paul J Pockros, Lynn M Frazier, Alexander Kuo, Anna S Lok, Mitchell L Shiffman, Ziv Ben Ari, Lucy Akushevich, Monika Vainorius, Mark S Sulkowski, Michael W Fried, David R NelsonPMID: 27565882
DOI: 10.1053/j.gastro.2016.08.004
2016
CIDEffectiveness and safety of sofosbuvir-based regimens for the treatment of chronic hepatitis C virus genotype 3 infection: results of the HCV-TARGET study (G3)Feld, Mann, Zeuzem, Kuo, Nelson, Di Bisceglie, Manns, Sherman, Frazier, Sterling, Mailliard.PMID: 27325691 PMCID: PMC4996139 [Available on 2017-09-15]
DOI: 10.1093/cid/ciw387
2016Liver InternationalSafety and Efficacy of Sofosbuvir-Containing Regimens in Hepatitis C Infected Patients with Reduced Renal FunctionVarun Saxena1; Farrukh M. Koraishy2, Meghan Sise3, Joseph K. Lim4, Monica Schmidt5, Raymond T. Chung3, Annmarie Liapakis4, David R. Nelson6, Michael W. Fried5, Norah Terrault1 and HCV-TARGETPMID: 26923436
DOI: 10.1111/liv.13102
2016Liver TransplantationInterferon-free Therapy for Genotype 1 Hepatitis C in Liver Transplant Recipients: Real World Experience from HCV-TARGETRobert S. Brown, Jr., M.D., M.P.H1., Jacqueline G. O’Leary M.D2, K. Rajender Reddy M.D3, Alexander Kuo4, Giuseppe Morelli5, R. Todd Stravitz6, Christine Durand7, Adrian M. Di Bisceglie8, Hugo E. Vargas9, Paul Kwo10, Catherine T. Frenette11, Thomas G. Stewart12, David R. Nelson5, Michael W. Fried12, and Norah Terrault  M.D13 on behalf of HCV-TARGET Study GroupPMID: 26519873
DOI: 10.1002/lt.24366
2016Gastro-enterologyEffectiveness of Simeprevir plus Sofosbuvir with or without ribavirin for the treatment of patients with HCV genotype 1 infection in real-world clinical practice:  The HCV TARGET StudySulkowski MS1, Vargas HE, Di Bisceglie AM, Kuo, PA, Reddy KR, Lim JK, Morelli G,  Darling JM, Feld JJ,  Brown RS, Frazier LM, Stewart TG, Fried MW,  Nelson DR, and Jacobson IM for the HCV-TARGET Study GroupPMID: 26497081 PMCID: PMC4727992 [Available on 2017-02-01]
DOI: 10.1053/j.gastro.2015.10.013
2015Alimentary Pharmacology and Therapeutics AP & TVIROLOGIC OUTCOMES AND ADHERENCE TO TREATMENT ALGORITHMS IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH BOCEPREVIR OR TELAPREVIRRichard K. Sterling,1 Alexander Kuo,2 Vinod K Rustgi,3 Mark S. Sulkowski,4 Thomas G. Stewart,5 Jonathan M. Fenkel,6 Hisham El-Genaidi,7 Mitchell A. Mah’moud,8 George M. Abraham,9 Paul Stewart, David R. Nelson, Michael W. Fried,5 Adrian M. Di Bisceglie10 for the HCV-TARGET Study Group doi:10.1111/apt.13095
2015Journal of HepatologyAdverse Events With Boceprevir or Telaprevir in Chronic Hepatitis C: Real-World Experience From HCV-TARGET.Stuart C. Gordon, MD,1* Andrew J. Muir, MD, MHS,2 Joseph K. Lim, MD,3 Brian Pearlman, MD,4 Curtis K. Argo, MD,5 Ananthakrishnan Ramani, MD,6 Benedict Maliakkal, MD,7 Imtiaz Alam,8 Thomas G. Stewart, MD,9 Monika Vainorius, MD,9 Joy Peter, RN,10 David R. Nelson, MD,10 Michael W. Fried, MD,9 K. Rajender Reddy, MD,11* for the HCV-TARGET Study Grouphttp://dx.doi.org/10.1016/j.jhep.2014.08.052
2014TransplantationSuccessful therapy of Hepatitis C with daclatasvir, pegylated interferon and ribavirin after failure with boceprevir based therapy in a liver transplant recipient with hyper-IgM syndromeK.Rajender Reddy, Amina Wirjosemito, Lorie Sinese, Eric Hughes, Patricia Mendez10.1097/TP.0000000000000076